Synchronized Regulation: Tandem Approvals Of Xalkori, Diagnostic Required Considerable Coordination
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer’s Xalkori may be a model for fast development of a targeted oncologic and companion diagnostic, but that model is likely to be more aspiration than reality for future drug/diagnostic combinations. Extensive co-operation was required to keep two sponsors and two review centers on the same page – an effort that reflected the drug’s highly promising efficacy in early studies and FDA’s confidence that confirmatory studies would back up an accelerated approval.
You may also be interested in...
Regulatory Round-Up: Drug Review Profiles From 2012
Each month, Pharmaceutical Approvals Monthly analyzes the FDA review process for a recent approval based on the NDA or BLA review documents. A detailed chronology of product development and listing of key reviewers accompany each profile. If you do not have access, contact customer care at 1-800-332-2181 for a free copy of any of these articles.
Regulatory Round-Up: Drug Review Profiles From 2012
Each month, Pharmaceutical Approvals Monthly analyzes the FDA review process for a recent approval based on the NDA or BLA review documents. A detailed chronology of product development and listing of key reviewers accompany each profile.
Evolution, Not Revolution, Marks Progress In Targeted Oncology Therapy – AACR
The American Association for Cancer Research’s second annual Cancer Progress Report makes the case that oncology progression is more a process of refinement than breakthrough right now.